500,000 Shares in LifeStance Health Group, Inc. $LFST Bought by Orbimed Advisors LLC

Orbimed Advisors LLC acquired a new stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) in the first quarter, HoldingsChannel.com reports. The firm acquired 500,000 shares of the company’s stock, valued at approximately $3,185,000.

A number of other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in LifeStance Health Group by 21.1% in the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock worth $124,608,000 after purchasing an additional 3,086,506 shares during the last quarter. Silversmith Partners I GP LLC purchased a new stake in shares of LifeStance Health Group during the 4th quarter valued at about $100,842,000. Dimensional Fund Advisors LP lifted its stake in shares of LifeStance Health Group by 16.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock worth $66,038,000 after purchasing an additional 1,461,215 shares during the period. Jennison Associates LLC lifted its stake in shares of LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after purchasing an additional 2,843,388 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of LifeStance Health Group by 27.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,118,027 shares of the company’s stock worth $43,071,000 after buying an additional 1,324,691 shares during the last quarter. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Price Performance

Shares of LFST stock opened at $10.90 on Monday. The company has a market capitalization of $4.23 billion, a price-to-earnings ratio of 181.67 and a beta of 1.12. LifeStance Health Group, Inc. has a one year low of $3.74 and a one year high of $11.76. The company’s fifty day moving average price is $9.33 and its 200-day moving average price is $7.82. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.48 and a quick ratio of 1.48.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The company had revenue of $403.48 million for the quarter, compared to analysts’ expectations of $387.46 million. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. Sell-side analysts expect that LifeStance Health Group, Inc. will post 0.12 EPS for the current fiscal year.

Insider Buying and Selling at LifeStance Health Group

In other news, Director Darren M. Black sold 5,899,661 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total value of $47,315,281.22. Following the completion of the transaction, the director owned 23,310,115 shares of the company’s stock, valued at $186,947,122.30. This represents a 20.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Eric Shuey sold 243,362 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total value of $1,951,763.24. Following the sale, the director owned 867,562 shares of the company’s stock, valued at $6,957,847.24. This represents a 21.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 7,687,394 shares of company stock valued at $63,579,701 over the last ninety days. 3.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Barclays boosted their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. KeyCorp upped their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of LifeStance Health Group in a report on Wednesday, May 27th. Finally, BTIG Research lifted their target price on LifeStance Health Group from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.50.

LifeStance Health Group Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.